Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma.

van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, Broekmans M, Stroeken P, Haneveld F, Hooijer GKJ, Savci-Heijink CD, Lakeman A, Volckmann R, van Sluis P, Valentijn LJ, Koster J, Versteeg R, van Nes J.

Nat Commun. 2019 Apr 4;10(1):1530. doi: 10.1038/s41467-019-09470-w.

2.

Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.

van Montfort T, van der Sluis R, Darcis G, Beaty D, Groen K, Pasternak AO, Pollakis G, Vink M, Westerhout EM, Hamdi M, Bakker M, van der Putten B, Jurriaans S, Prins JH, Jeeninga R, Thomas AAM, Speijer D, Berkhout B.

EBioMedicine. 2019 Apr;42:97-108. doi: 10.1016/j.ebiom.2019.02.014. Epub 2019 Feb 26.

3.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2019 Apr;38(15):2690-2705. doi: 10.1038/s41388-018-0595-3. Epub 2018 Dec 11.

PMID:
30538293
4.

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R.

Nat Genet. 2017 Aug;49(8):1261-1266. doi: 10.1038/ng.3899. Epub 2017 Jun 26.

PMID:
28650485
5.

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.

Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME.

Oncotarget. 2016 May 10;7(19):27946-58. doi: 10.18632/oncotarget.8547.

6.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

7.

Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.

Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW.

J Pharm Biomed Anal. 2015 Mar 25;107:403-8. doi: 10.1016/j.jpba.2015.01.026. Epub 2015 Jan 19.

PMID:
25659532
8.

FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.

Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM.

Cancer Res. 2013 Apr 1;73(7):2189-98. doi: 10.1158/0008-5472.CAN-12-3767. Epub 2013 Feb 1.

9.

Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.

Lamers F, Schild L, Koster J, Speleman F, Øra I, Westerhout EM, van Sluis P, Versteeg R, Caron HN, Molenaar JJ.

BMC Cancer. 2012 Jul 12;12:285. doi: 10.1186/1471-2407-12-285.

10.

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R.

Nature. 2012 Feb 22;483(7391):589-93. doi: 10.1038/nature10910.

PMID:
22367537
11.

Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.

Lamers F, Schild L, den Hartog IJ, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ.

Eur J Cancer. 2012 Nov;48(16):3093-103. doi: 10.1016/j.ejca.2012.01.037. Epub 2012 Feb 25.

12.

Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis.

Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R.

Genes Chromosomes Cancer. 2012 Jan;51(1):10-9. doi: 10.1002/gcc.20926. Epub 2011 Oct 27.

PMID:
22034077
13.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.

Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.

14.

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12968-73. doi: 10.1073/pnas.0901418106. Epub 2009 Jun 12.

15.

HIV-1 latency in actively dividing human T cell lines.

Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B.

Retrovirology. 2008 Apr 25;5:37. doi: 10.1186/1742-4690-5-37.

16.

RNA interference against viruses: strike and counterstrike.

Haasnoot J, Westerhout EM, Berkhout B.

Nat Biotechnol. 2007 Dec;25(12):1435-43. Review.

PMID:
18066040
17.

A systematic analysis of the effect of target RNA structure on RNA interference.

Westerhout EM, Berkhout B.

Nucleic Acids Res. 2007;35(13):4322-30. Epub 2007 Jun 18.

18.

The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference.

Westerhout EM, ter Brake O, Berkhout B.

Retrovirology. 2006 Sep 4;3:57.

19.

A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication.

Westerhout EM, Vink M, Haasnoot PC, Das AT, Berkhout B.

Mol Ther. 2006 Aug;14(2):268-75. Epub 2006 May 11.

20.

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B.

Nucleic Acids Res. 2005 Feb 1;33(2):796-804. Print 2005.

21.

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition.

Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B.

J Virol. 2004 Mar;78(5):2601-5.

22.

Viral immune evasion: a masterpiece of evolution.

Vossen MT, Westerhout EM, Söderberg-Nauclér C, Wiertz EJ.

Immunogenetics. 2002 Nov;54(8):527-42. Epub 2002 Oct 24. Review.

PMID:
12439615

Supplemental Content

Loading ...
Support Center